Navigation Links
Zerenex (ferric citrate) long-term Phase 3 study results published in JASN
Date:7/24/2014

New York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication of results from the long-term, randomized, active control Phase 3 study of Zerenex (ferric citrate), the Company's investigational oral ferric iron-based phosphate binder, for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis. The PERFECTED study (PhosphatE binding and iRon delivery with FErric CiTrate in EsrD) was published online today in the Journal of the American Society of Nephrology (JASN).

This Phase 3 study was a multicenter, randomized, open-label trial in 441 ESRD patients on hemodialysis or peritoneal dialysis designed to determine the safety and efficacy of Zerenex as a treatment to reduce serum phosphorus as well as raise iron stores and reduce intravenous (IV) iron and erythropoietin-stimulating agents (ESA) usage.

Zerenex met the study's primary end-point demonstrating a highly statistically significant change in serum phosphorus versus placebo over the four-week Placebo Control Period. Using a sequential gatekeeping strategy for the key pre-defined secondary end-points, Zerenex also demonstrated statistically significant increases in serum ferritin and transferrin saturation (TSAT), and significant reductions in the use of IV iron and ESAs, versus an active control of Renvela (sevelamer carbonate) and/or Phoslo (calcium acetate) over the 52-week Active Control Period of the study. In addition, mean hemoglobin levels were higher in subjects treated with Zerenex as compared to subjects treated with active control.

"Zerenex effectively reduces serum phosphorus levels within the KDOQI range (3.5 mg/dL to 5.5 mg/dL) while having the additional patient benefits of increasing iron stores and decreasing the need for IV iron and ESAs, while maintaining hemoglobin levels," said Julia Lewis, MD, lead investigator, nephrologist and Professor of Medici
'/>"/>

Contact: Amy Sullivan
amy.sullivan@keryx.com
617-466-3447
Keryx Biopharmaceuticals, Inc.
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. The Holistic Sanctuary Issues Response to The Irish Times About the Risks of Long-term Methadone Use
3. Circassias Short-Course House Dust Mite Allergy Treatment Achieves Significant Long-Term Symptom Reduction
4. Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
5. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
6. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
7. University of Colorado Cancer Center Review Shows Long-term Side-effects of New, Targeted Therapies in Pediatric Cancer Patients
8. Genomatica, Inc., Award-Winning Industrial Biotechnology Pioneer, Selects Alexandria Real Estate Equities, Inc. for Long-Term, Mission-Critical R&D Facility and Corporate Headquarters
9. Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures
10. Resolve Initiates Phase 2 Clinical Study in SLE
11. Generex Announces Completion of Enrollment of Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Mass. , Sept. 22, 2014 ... GEVA ), a biopharmaceutical company developing therapeutic ... of Robert Bazemore as Chief Operating ... , President and Chief Executive Officer, Robert will ... company,s lead program, sebelipase alfa for LAL Deficiency, ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Entries are ... Prism Awards for Photonics Innovation . The international ... multi-billion dollar optics and photonics industry, and is sponsored ... photonics , and Photonics Media . , The ... versatility of photonics, said SPIE CEO Eugene Arthurs. , ...
(Date:9/19/2014)... NEW YORK, September 18, 2014 Scientists at NYU ... boost dramatically the efficiency of the process for turning ... three well-known compounds, including vitamin C. Using the new ... stem cells obtained from adult skin cells by more ... their technique is efficient and reliable, and thus should ...
(Date:9/19/2014)... Sept. 19, 2014  Nektar Therapeutics (NASDAQ: ... studies characterizing the analgesic profiles of a series ... receptor agonist molecules. The preclinical research candidates were ... platform. The analgesic properties of kappa ... literature. 1,2 Kappa opioid receptors are expressed ...
Breaking Biology Technology:Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4Entry deadline is 10 October for international photonics Prism Awards 2Entry deadline is 10 October for international photonics Prism Awards 3Entry deadline is 10 October for international photonics Prism Awards 4NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5
... detect broken bones, tumors and dental cavities, analyze atoms in ... knew they could cause crystals to form? A team ... the formation of a new type of crystal: charged cylindrical ... which is unknown in crystals. Similar phenomena may occur naturally ...
... , , , , ... 25 /PRNewswire-Asia/ -- China,Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: ... distributor and,retailer of Chinese traditional medicines, pharmaceutical products, natural,health products, ... The Company today announced that it plans to open twenty ...
... , ... ,Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in ... important milestone in the official,marketing authorisation process for ... lipase deficiency (LPLD). The submission,of the Glybera(R) Marketing ...
Cached Biology Technology:Surprising discovery: X-rays drive formation of new crystals 2China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share 2China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share 3China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share 4EMA Starts Formal Review of Glybera(R) Dossier 2EMA Starts Formal Review of Glybera(R) Dossier 3
(Date:9/18/2014)... N.Y. A sleep-promoting circuit located deep in the ... sleep. Discovered by researchers at Harvard School of Medicine ... Biomedical Sciences, this is only the second "sleep node" ... be both necessary and sufficient to produce deep sleep. ... , the study demonstrates that fully half of all ...
(Date:9/18/2014)... robotic system that can operate inside the bore of ... of a biomedical research partnership program at Brigham and ... if the robot, in conjunction with real-time MRI images, ... costly, and less discomforting for the patient. The novel ... therapies with greater precision. , Developed by a team ...
(Date:9/18/2014)... many times it,s demonstrated, it,s still hard to ... But by using a signaling system called "quorum ... to suit their population. In short, some bacteria ... act accordingly. , Once the population of quorum-sensing ... innocuous to pathogenic, or from unhelpful to helpful. ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... of the world,s biggest killers for as long as records ... the rise, there is a renewed push to find different ... have stepped up to the plate to answer the call. ... department of chemical and biomolecular engineering, recently were awarded a ...
... Now computers are at it again, but this ... itself. An interdisciplinary team of scientists at Vanderbilt ... taken a major step toward this goal by demonstrating ... a biological system and derive the basic mathematical equations ...
... has been associated with cognitive decline, characterized by a ... thought-processing speed. But in a study of 300 post-menopausal ... in Argentina, obese participants in the study performed better ... leading researchers to speculate about the role of sex ...
Cached Biology News:UH engineers finding new ways to fight malaria with DOD grant 2Robot biologist solves complex problem from scratch 2Robot biologist solves complex problem from scratch 3Association between menopause, obesity and cognitive impairment 2
Mitochondria/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
... increasing age, the autofluorescent pigment lipofuscin ... cell types, including neurons. The presence ... use of fluorescence microscopy in the ... broad excitation and emission spectra, which ...
... the family of calcium binding proteins such as ... of an alpha and beta chain whereas S100B ... protein is also expressed in the antigen presenting ... and interdigitating reticulum cells in the paracortex of ...
LEAF™ Purified anti-human/mouse/rat ICOS...
Biology Products: